The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Human Vaccines Administered Orally Market Research Report 2025
Synopsis
Oral vaccines are safe and easy to administer and convenient for all ages. They have been successfully developed to protect from many infectious diseases acquired through oral transmission. Oral delivery of vaccines represents the most attractive mode of administration over other routes of delivery due to the fact that the oral vaccination is noninvasive, safe and simple to execute, showing good patient compliance and clinical practicality.
The global Human Vaccines Administered Orally market was valued at US$ 1874 million in 2023 and is anticipated to reach US$ 2746.3 million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Human Vaccines Administered Orally, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Vaccines Administered Orally.
Report Scope
The Human Vaccines Administered Orally market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Vaccines Administered Orally market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Vaccines Administered Orally manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Segment by Type
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Segment by Application
Public
Private
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Vaccines Administered Orally manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Vaccines Administered Orally in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Oral vaccines are safe and easy to administer and convenient for all ages. They have been successfully developed to protect from many infectious diseases acquired through oral transmission. Oral delivery of vaccines represents the most attractive mode of administration over other routes of delivery due to the fact that the oral vaccination is noninvasive, safe and simple to execute, showing good patient compliance and clinical practicality.
The global Human Vaccines Administered Orally market was valued at US$ 1874 million in 2023 and is anticipated to reach US$ 2746.3 million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Human Vaccines Administered Orally, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Vaccines Administered Orally.
Report Scope
The Human Vaccines Administered Orally market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Vaccines Administered Orally market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Vaccines Administered Orally manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Segment by Type
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Segment by Application
Public
Private
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Vaccines Administered Orally manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Vaccines Administered Orally in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Human Vaccines Administered Orally Market Overview
1.1 Product Overview and Scope of Human Vaccines Administered Orally
1.2 Human Vaccines Administered Orally Segment by Type
1.2.1 Global Human Vaccines Administered Orally Market Value Comparison by Type (2024-2030)
1.2.2 Rotavirus Vaccine
1.2.3 Cholera Vaccine
1.2.4 Oral Polio Vaccine
1.3 Human Vaccines Administered Orally Segment by Application
1.3.1 Global Human Vaccines Administered Orally Market Value by Application: (2024-2030)
1.3.2 Public
1.3.3 Private
1.4 Global Human Vaccines Administered Orally Market Size Estimates and Forecasts
1.4.1 Global Human Vaccines Administered Orally Revenue 2019-2030
1.4.2 Global Human Vaccines Administered Orally Sales 2019-2030
1.4.3 Global Human Vaccines Administered Orally Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Human Vaccines Administered Orally Market Competition by Manufacturers
2.1 Global Human Vaccines Administered Orally Sales Market Share by Manufacturers (2019-2024)
2.2 Global Human Vaccines Administered Orally Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Human Vaccines Administered Orally Average Price by Manufacturers (2019-2024)
2.4 Global Human Vaccines Administered Orally Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Vaccines Administered Orally, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Vaccines Administered Orally, Product Type & Application
2.7 Human Vaccines Administered Orally Market Competitive Situation and Trends
2.7.1 Human Vaccines Administered Orally Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Vaccines Administered Orally Players Market Share by Revenue
2.7.3 Global Human Vaccines Administered Orally Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Vaccines Administered Orally Retrospective Market Scenario by Region
3.1 Global Human Vaccines Administered Orally Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Human Vaccines Administered Orally Global Human Vaccines Administered Orally Sales by Region: 2019-2030
3.2.1 Global Human Vaccines Administered Orally Sales by Region: 2019-2024
3.2.2 Global Human Vaccines Administered Orally Sales by Region: 2025-2030
3.3 Global Human Vaccines Administered Orally Global Human Vaccines Administered Orally Revenue by Region: 2019-2030
3.3.1 Global Human Vaccines Administered Orally Revenue by Region: 2019-2024
3.3.2 Global Human Vaccines Administered Orally Revenue by Region: 2025-2030
3.4 North America Human Vaccines Administered Orally Market Facts & Figures by Country
3.4.1 North America Human Vaccines Administered Orally Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Human Vaccines Administered Orally Sales by Country (2019-2030)
3.4.3 North America Human Vaccines Administered Orally Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Human Vaccines Administered Orally Market Facts & Figures by Country
3.5.1 Europe Human Vaccines Administered Orally Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Human Vaccines Administered Orally Sales by Country (2019-2030)
3.5.3 Europe Human Vaccines Administered Orally Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Vaccines Administered Orally Market Facts & Figures by Country
3.6.1 Asia Pacific Human Vaccines Administered Orally Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Human Vaccines Administered Orally Sales by Country (2019-2030)
3.6.3 Asia Pacific Human Vaccines Administered Orally Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Human Vaccines Administered Orally Market Facts & Figures by Country
3.7.1 Latin America Human Vaccines Administered Orally Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Human Vaccines Administered Orally Sales by Country (2019-2030)
3.7.3 Latin America Human Vaccines Administered Orally Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Vaccines Administered Orally Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Vaccines Administered Orally Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Human Vaccines Administered Orally Sales by Country (2019-2030)
3.8.3 Middle East and Africa Human Vaccines Administered Orally Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Vaccines Administered Orally Sales by Type (2019-2030)
4.1.1 Global Human Vaccines Administered Orally Sales by Type (2019-2024)
4.1.2 Global Human Vaccines Administered Orally Sales by Type (2025-2030)
4.1.3 Global Human Vaccines Administered Orally Sales Market Share by Type (2019-2030)
4.2 Global Human Vaccines Administered Orally Revenue by Type (2019-2030)
4.2.1 Global Human Vaccines Administered Orally Revenue by Type (2019-2024)
4.2.2 Global Human Vaccines Administered Orally Revenue by Type (2025-2030)
4.2.3 Global Human Vaccines Administered Orally Revenue Market Share by Type (2019-2030)
4.3 Global Human Vaccines Administered Orally Price by Type (2019-2030)
5 Segment by Application
5.1 Global Human Vaccines Administered Orally Sales by Application (2019-2030)
5.1.1 Global Human Vaccines Administered Orally Sales by Application (2019-2024)
5.1.2 Global Human Vaccines Administered Orally Sales by Application (2025-2030)
5.1.3 Global Human Vaccines Administered Orally Sales Market Share by Application (2019-2030)
5.2 Global Human Vaccines Administered Orally Revenue by Application (2019-2030)
5.2.1 Global Human Vaccines Administered Orally Revenue by Application (2019-2024)
5.2.2 Global Human Vaccines Administered Orally Revenue by Application (2025-2030)
5.2.3 Global Human Vaccines Administered Orally Revenue Market Share by Application (2019-2030)
5.3 Global Human Vaccines Administered Orally Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Human Vaccines Administered Orally Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Human Vaccines Administered Orally Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Human Vaccines Administered Orally Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GSK Human Vaccines Administered Orally Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Human Vaccines Administered Orally Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Human Vaccines Administered Orally Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Lanzhou Institute
6.4.1 Lanzhou Institute Corporation Information
6.4.2 Lanzhou Institute Description and Business Overview
6.4.3 Lanzhou Institute Human Vaccines Administered Orally Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Lanzhou Institute Human Vaccines Administered Orally Product Portfolio
6.4.5 Lanzhou Institute Recent Developments/Updates
6.5 Serum Institute
6.5.1 Serum Institute Corporation Information
6.5.2 Serum Institute Description and Business Overview
6.5.3 Serum Institute Human Vaccines Administered Orally Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Serum Institute Human Vaccines Administered Orally Product Portfolio
6.5.5 Serum Institute Recent Developments/Updates
6.6 Valneva
6.6.1 Valneva Corporation Information
6.6.2 Valneva Description and Business Overview
6.6.3 Valneva Human Vaccines Administered Orally Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Valneva Human Vaccines Administered Orally Product Portfolio
6.6.5 Valneva Recent Developments/Updates
6.7 Shanghai United Cell
6.6.1 Shanghai United Cell Corporation Information
6.6.2 Shanghai United Cell Description and Business Overview
6.6.3 Shanghai United Cell Human Vaccines Administered Orally Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Shanghai United Cell Human Vaccines Administered Orally Product Portfolio
6.7.5 Shanghai United Cell Recent Developments/Updates
6.8 Bibcol
6.8.1 Bibcol Corporation Information
6.8.2 Bibcol Description and Business Overview
6.8.3 Bibcol Human Vaccines Administered Orally Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Bibcol Human Vaccines Administered Orally Product Portfolio
6.8.5 Bibcol Recent Developments/Updates
6.9 PaxVax
6.9.1 PaxVax Corporation Information
6.9.2 PaxVax Description and Business Overview
6.9.3 PaxVax Human Vaccines Administered Orally Sales, Revenue and Gross Margin (2019-2024)
6.9.4 PaxVax Human Vaccines Administered Orally Product Portfolio
6.9.5 PaxVax Recent Developments/Updates
6.10 Vabiotech
6.10.1 Vabiotech Corporation Information
6.10.2 Vabiotech Description and Business Overview
6.10.3 Vabiotech Human Vaccines Administered Orally Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Vabiotech Human Vaccines Administered Orally Product Portfolio
6.10.5 Vabiotech Recent Developments/Updates
6.11 Tiantan Biological
6.11.1 Tiantan Biological Corporation Information
6.11.2 Tiantan Biological Human Vaccines Administered Orally Description and Business Overview
6.11.3 Tiantan Biological Human Vaccines Administered Orally Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Tiantan Biological Human Vaccines Administered Orally Product Portfolio
6.11.5 Tiantan Biological Recent Developments/Updates
6.12 EuBiologics
6.12.1 EuBiologics Corporation Information
6.12.2 EuBiologics Human Vaccines Administered Orally Description and Business Overview
6.12.3 EuBiologics Human Vaccines Administered Orally Sales, Revenue and Gross Margin (2019-2024)
6.12.4 EuBiologics Human Vaccines Administered Orally Product Portfolio
6.12.5 EuBiologics Recent Developments/Updates
6.13 Panacea Biotec Ltd
6.13.1 Panacea Biotec Ltd Corporation Information
6.13.2 Panacea Biotec Ltd Human Vaccines Administered Orally Description and Business Overview
6.13.3 Panacea Biotec Ltd Human Vaccines Administered Orally Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Panacea Biotec Ltd Human Vaccines Administered Orally Product Portfolio
6.13.5 Panacea Biotec Ltd Recent Developments/Updates
6.14 Bio-Med
6.14.1 Bio-Med Corporation Information
6.14.2 Bio-Med Human Vaccines Administered Orally Description and Business Overview
6.14.3 Bio-Med Human Vaccines Administered Orally Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Bio-Med Human Vaccines Administered Orally Product Portfolio
6.14.5 Bio-Med Recent Developments/Updates
6.15 Halfkin Bio-Pharmaceuticals
6.15.1 Halfkin Bio-Pharmaceuticals Corporation Information
6.15.2 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Description and Business Overview
6.15.3 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Portfolio
6.15.5 Halfkin Bio-Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Vaccines Administered Orally Industry Chain Analysis
7.2 Human Vaccines Administered Orally Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Vaccines Administered Orally Production Mode & Process
7.4 Human Vaccines Administered Orally Sales and Marketing
7.4.1 Human Vaccines Administered Orally Sales Channels
7.4.2 Human Vaccines Administered Orally Distributors
7.5 Human Vaccines Administered Orally Customers
8 Human Vaccines Administered Orally Market Dynamics
8.1 Human Vaccines Administered Orally Industry Trends
8.2 Human Vaccines Administered Orally Market Drivers
8.3 Human Vaccines Administered Orally Market Challenges
8.4 Human Vaccines Administered Orally Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
